Hydrocortisone, Iodoquinol 10 mg/g; 10 mg/g Cream, 1 tube — NDC 52187-532-01 (Billing 52187-0532-01)
This is a package of 1 tube of Hydrocortisone, Iodoquinol 10 mg/g; 10 mg/g Cream from KMM Pharmaceuticals, LLC, no longer marketed (first marketed Oct 2018), no longer in the FDA NDC Directory, this package's marketing ended Aug 2026. It is this product's only package size.
NDC database record
One package, one record: these facts belong to NDC 52187-532-01 alone.
- Record
- FDA NDC Directory package listing · Human prescription drug
- Code segments
- 52187 labeler · 532 product · 01 package
- Package marketed since
- Oct 16, 2018
- Package marketing ended
- Aug 31, 2026
- Sample package
- No — commercial package
- Barcode (UPC-A, from the NDC)
- 3 5218753201 1
- FDA record last changed
- Jul 24, 2026
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification
- GSN (GCN sequence number): 007138
- GCN: 84261
- GPI-14 (Medi-Span): 90159902153710
- HICL (First Databank): 003113
- AHFS class code: 52:08.08.00
- RxCUI (RxNorm): 310870
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 8, 2026
- FDA label on DailyMed · label index refreshed Oct 6, 2026
- RxNorm (NLM RxNav) · catalog refreshed Oct 1, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Oct 8, 2026
RxNorm drug class
This medicine belongs to the Quinoline derivatives class.
Where does this data come from?
- RxClass (NLM) · catalog refreshed Oct 1, 2026
Clinical
This is a topical cream containing hydrocortisone and iodoquinol. Hydrocortisone is a corticosteroid typically used to reduce inflammation and itching in skin conditions. Iodoquinol is an antimicrobial agent commonly used in dermatology products for its antibacterial and antifungal properties. The combination is intended for application to affected skin areas. Please note this product is marketed without an approved FDA application.
Patient education
Supplement & herbal interactions
Where does this data come from?
- MedlinePlus (NLM) · refreshed Oct 1, 2026
- FDA label on DailyMed · label index refreshed Oct 6, 2026
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per g | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | Not in the retail survey — common for institutional, discontinued, or low-volume packs. | |
| Medicaid paysCMS SDUD · 12 mo | No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data. | |
| Medicare drug plans payPart D · quarterly | No Part D plan price is available for this NDC in our data. | |
Where does this data come from?
- CMS NADAC weekly file
- CMS ASP pricing files · refreshed Sep 20, 2026
- CMS Medicaid State Drug Utilization Data · refreshed Oct 8, 2026
- CMS Part D plan pricing files · refreshed Sep 24, 2026
- VA National Acquisition Center price file
Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Marketing end | Status |
|---|---|---|---|---|
| 52187-0532-01 You're viewing this Main listing | 1 TUBE in 1 CARTON / 28.4 g in 1 TUBE | 2018-10-16 | Aug 31, 2026 | Discontinued by firm |
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Hydrocortisone, Iodoquinol 10 mg/g; 10 mg/gthis 52187-0532-01 | KMM | 1 tube | — | — | Discontinued | — |
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 8, 2026
- FDA Orange Book · refreshed Oct 3, 2026
- CMS NADAC weekly file
Availability & generic status
We did not find an FDA-approved generic match for this exact strength, form and route.
Where does this data come from?
- FDA Orange Book · refreshed Oct 3, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
Where does this data come from?
IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.- FDA label on DailyMed · label index refreshed Oct 6, 2026
- FDA openFDA NDC Directory · synced Oct 8, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
Manufacturer & labeler
More NDCs from KMM Pharmaceuticals, LLC labeler code 52187
- Salicylic Acid 285 mg/mL Solution NDC 52187-522-10
- Xalix Salicylic Acid 280 mg/g Solution NDC 52187-525-10
- SALICYLIC ACID 260 mg/mL Liquid NDC 52187-526-10
- SODIUM SULFACETAMIDE, SULFUR 90 mg/mL; 40 mg/mL Liquid NDC 52187-530-16
- SODIUM SULFACETAMIDE, SULFUR 40 mg/mL; 80 mg/mL Suspension NDC 52187-531-16
- Sodium Sulfacetamide, Sulfur 100 mg/g; 50 mg/g Rinse NDC 52187-536-06
- Sodium Sulfacetamide 9.8% and Sulfur 4.8% Cleanser 48 mg/g; 98 mg/g Liquid NDC 52187-546-10
- Sulfacetamide Sodium, Sulfur 98 mg/g; 48 mg/g Cream NDC 52187-547-02
- Sulfacetamide Sodium, Sulfur 98 mg/g; 48 mg/g Lotion NDC 52187-548-02
- SELENIUM SULFIDE 23 mg/mL Shampoo NDC 52187-550-06
- Hydrocortisone Acetate, Iodoquinol 19 mg/g; 10 mg/g Cream NDC 52187-551-30
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 8, 2026
- Drugs@FDA
Full prescribing information FDA SPL
🎯 Indications and Usage ▾
INDICATIONS: Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: “Possibly” Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); moniliasis; intertrigo.
Final classification of the less-than-effective indications requires further investigation.
⏱️ Dosage and Administration ▾
DOSAGE AND ADMINISTRATION: Apply to affected area 3 to 4 times daily in accordance with physician’s directions.
⛔ Contraindications ▾
CONTRAINDICATIONS: This product is contraindicated in persons with known or suspected hypersensitivity to any of the ingredients of the product.
⚠️ Warnings ▾
WARNING: FOR EXTERNAL USE ONLY.
🤒 Adverse Reactions ▾
ADVERSE REACTIONS: The following local adverse reactions are reported infrequently with topical corticosteroids. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infections, skin atrophy, striae and miliaria.
🧬 Clinical Pharmacology ▾
CLINICAL PHARMACOLOGY: Hydrocortisone has anti-inflammatory, antipruritic and vasoconstrictive properties. While the mechanism of anti-inflammatory activity is unclear, there is evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in humans. Iodoquinol has both antifungal and antibacterial properties.
Pharmacokinetics: The extent of percutaneous absorption of topical steroids is determined by many factors including the vehicle, the integrity of the epidermal barrier and the use of occlusive dressings. Hydrocortisone can be absorbed from normal intact skin. Inflammation and/or other inflammatory disease processes in the skin increase percutaneous absorption.
Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. Once absorbed through the skin, hydrocortisone is metabolized in the liver and most body tissue to hydrogenated and degraded forms such as tetrahydrocortisone and tetrahydrocortisol. These are excreted in the urine, mainly conjugated as glucuronides, together with a very small proportion of unchanged hydrocortisone.
There are no data available regarding the percutaneous absorption of iodoquinol; however, following oral administration, 3-5% of the dose was recovered in the urine as a glucuronide.
📦 How Supplied / Storage and Handling ▾
HOW SUPPLIED: 1 oz. tubes, NDC 52187-532-01 To report a serious adverse event or obtain product information, call 1-855-899-4237. Manufactured for: KMM Pharmaceuticals, LLC 1000 N. West Street Suite 1200, #1021 Wilmington, DE 19801 1800088 v1 Rev. 08/2018
📦 Storage and Handling ▾
STORAGE: Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C to 30°C (between 59°F to 86°F). Brief exposure to temperatures up to 40°C (104°F) may be tolerated provided the mean kinetic temperature does not exceed 25°C (77°F); however, such exposure should be minimized. Keep container tightly closed. NOTICE: Protect from freezing and excessive heat.
📋 Description ▾
DESCRIPTION: Each gram contains 10 mg of hydrocortisone and 10 mg of iodoquinol in a vehicle consisting of: aloe vera powder, aminomethyl propanol 95%, benzyl alcohol, carbomer, citric acid anhydrous, D&C Yellow #10, FD&C Blue #1, glycerin, glyceryl polymethacrylate, magnesium aluminum silicate, palmitoyl oligopeptide, PPG-20 methyl glucose ether, propylene glycol, purified water and SD 40B alcohol. Chemically, hydrocortisone is [Pregn-4-ene-3, 20-dione, 11, 17, 21-trihydroxy-,(11ß)-] with the molecular formula (C 21 H 30 O 5 ) and is represented by the following structural formula: and iodoquinol, 5,7-diiodo-8-quinolinol (C 9 H 5 I 2 NO) is represented by the following structural formula: Hydrocortisone is an anti-inflammatory and antipruritic agent, while iodoquinol is an antifungal and antibacterial agent. chem1 chem2
⚠️ Precautions ▾
PRECAUTIONS: NOT FOR OPHTHALMIC USE. KEEP OUT OF REACH OF CHILDREN. Avoid contact with eyes, lips and mucous membranes.
Information for Patients: If irritation develops, the use of this product should be discontinued and appropriate therapy instituted. Staining of the skin, hair and fabrics may occur. Not intended for use on infants or under diapers or occlusive dressings.
If extensive areas are treated or if the occlusive dressing technique is used, the possibility exists of increased systemic absorption of the corticosteroid, and suitable precautions should be taken. Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity. Iodoquinol may be absorbed through the skin and interfere with thyroid function tests.
If such tests are contemplated, wait at least one month after discontinuance of therapy to perform these tests. The ferric chloride test for phenylketonuria (PKU) can yield a false positive result if iodoquinol is present in the diaper or urine. Prolonged use may result in overgrowth of non-susceptible organisms requiring appropriate therapy.
Carcinogenesis, Mutagenesis and Impairment of Fertility: Long-term animal studies for carcinogenic potential have not been performed on this product to date. In vitro studies to determine mutagenicity with hydrocortisone have revealed negative results. Mutagenicity studies have not been performed with iodoquinol.
Pregnancy: Category C. Animal reproduction studies have not been conducted with this product. It is also not known whether this product can affect reproduction capacity or cause fetal harm when administered to a pregnant woman.
This product should be used by a pregnant woman only if clearly needed or when potential benefits outweigh potential hazards to the fetus. Nursing Mothers: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when this product is administered to a nursing woman.
Pediatric Use: Safety and effectiveness in pediatric patients under the age of 12 have not been established.
📄 Package Label / Principal Display Panel ▾
carton
About this NDC listing & data coverage
Listed without an FDA application
This product's marketing category indicates it is marketed without an approved FDA application (no NDA, ANDA, or BLA on file). Having an NDC does not by itself establish FDA approval — the NDC Directory is a listing system, not an approval decision. Approval-linked data such as Orange Book therapeutic-equivalence ratings therefore does not apply.
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | ✓ Available |
| Package photos | — Not published for this NDC No photo available yet for this listing. |
| Inactive ingredients (structured) | — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available. |
| NADAC pharmacy acquisition price (CMS) | — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey. |
| Orange Book / therapeutic-equivalence data | — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope. |
| HCPCS J-code billing crosswalk | — Not published for this NDC Most self-administered / retail products have no J-code — that is normal. |
| Medicaid utilization (CMS SDUD) | — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold. |